**DECLARATION OF THE END OF A STUDY**

(For all studies except clinical trials of investigational medicinal products)

To be completed in typescript by the Chief Investigator and submitted to the Research Ethics Committee that gave a favourable opinion of the research (“the main REC”) within 90 days of the conclusion of the study or within 15 days of early termination. For questions with Yes/No options please indicate answer in bold type.

**1. Details of Chief Investigator**

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |
| Telephone: |  |
| Email: |  |
| Fax: |  |

**2. Details of study**

|  |  |
| --- | --- |
| Full title of study: |  |
| Research sponsor: |  |
| Name of main REC: |  |
| Main REC reference number: |  |

**3. Study duration**

|  |  |
| --- | --- |
| Date study commenced: |  |
| Date study ended: |  |
| Did this study terminate prematurely? | *Yes / No**If yes please complete sections 4, 5 & 6, if no please go direct to section 7.* |

**4. Recruitment**

|  |  |
| --- | --- |
| Number of participants recruited |  |
| Proposed number of participants to be recruited at the start of the study |  |
| If different, please state the reason or this |  |

**5. Circumstances of early termination**

|  |  |
| --- | --- |
| What is the justification for this early termination? |  |

**6. Temporary halt**

|  |  |
| --- | --- |
| Is this a temporary halt to the study? | *Yes / No* |
| If yes, what is the justification for temporarily halting the study? When do you expect the study to re-start? | *e.g. Safety, difficulties recruiting participants, trial has not commenced, other reasons.* |

**7. Potential implications for research participants**

|  |  |
| --- | --- |
| Are there any potential implications for research participants as a result of terminating/halting the study prematurely? Please describe the steps taken to address them. |  |

**8. Final report on the research**

|  |  |
| --- | --- |
| Is a summary of the final report on the research enclosed with this form? | *Yes / No**If no, please forward within 12 months of the end of the study.* |

**9. Declaration**

|  |  |
| --- | --- |
| Signature of Chief Investigator: |  |
| Print name: |  |
| Date of submission: |  |